Price
1,724.7
-2.04%52W Range
Market Cap
₹28,523.56 Cr
Traded: ₹47.41 Cr (0.17%) 0.0x
Free Float: ₹1,591.61 Cr (2.98% of FF traded)
Volume · 60D trend
2.75 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +16.0% | +27.0% | -- | -- | Accelerating |
| Sales | -- | +41.0% | +65.0% | -- | +47.0% | Stable |
| Profit | -- | +52.0% | +155.0% | -- | +89.0% | Stable |
| Return | -- | -- | -- | -- | -- | -- |
Quarterly Results
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 534 | 514 | 476 | 412 | 352 | 358 | 313 | 296 |
| Expenses | 405 | 395 | 367 | 318 | 273 | 286 | 244 | 234 |
| Operating Profit | 129 | 119 | 108 | 94 | 79 | 72 | 70 | 62 |
| OPM % | 24.0% | 23.0% | 23.0% | 23.0% | 22.0% | 20.0% | 22.0% | 21.0% |
| Other Income | 6 | 3 | 4 | 1 | 1 | 0 | 0 | 3 |
| Interest | 9 | 10 | 10 | 11 | 11 | 12 | 8 | 7 |
| Depreciation | 15 | 12 | 12 | 12 | 10 | 10 | 9 | 8 |
| Profit Before Tax | 110 | 99 | 91 | 72 | 60 | 51 | 53 | 49 |
| Tax % | 23.0% | 22.0% | 20.0% | 25.0% | 27.0% | 29.0% | 28.0% | 30.0% |
| Net Profit | 85 | 77 | 73 | 54 | 43 | 36 | 38 | 34 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 5.1 | 4.7 | 4.4 | 3.5 | 2.8 | 2.4 | 2.5 | 2.3 |
| Sales Growth (YoY) | 52.0% | 43.0% | 52.0% | 39.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 8.0% | 15.5% | 17.1% | -1.7% | 14.4% | 5.7% | -- |
| OP Growth (YoY) | 63.3% | 65.3% | 54.3% | 51.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | 8.4% | 10.2% | 14.9% | 19.0% | 9.7% | 2.9% | 12.9% | -- |
| Profit Growth (YoY) | 96.0% | 112.0% | 91.0% | 56.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 98.3% | 76.8% | 53.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 5.4% | 26.6% | 24.2% | 19.6% | -6.0% | 10.1% | -- |
| OP Margin | -- | 23.1% | 22.7% | 22.8% | 22.4% | 20.1% | 22.4% | 20.9% |
| Net Margin | -- | 15.0% | 15.3% | 13.1% | 12.2% | 10.1% | 12.1% | 11.5% |
| Material Cost % | 31.6% | 32.9% | 33.1% | 30.7% | 29.2% | 31.2% | 31.5% | 26.7% |
| Employee Cost % | 16.0% | 13.3% | 14.0% | 15.4% | 16.5% | 15.8% | 17.2% | 17.3% |
| P/S | 14.73 | 15.27 | 10.67 | -- | -- | -- | -- | -- |
| P/E | 97.50 | 105.27 | 76.07 | -- | -- | -- | -- | -- |
| P/B | 22.13 | 20.77 | 25.61 | -- | -- | -- | -- | -- |
Exchange Filings
50Trascript of Earnings Call Q1 FY 2026-27
Newspaper Publication
Audio Recording of earnings conference call for the quarter ended 30th June, 2026
Monitoring Agency Report for the Quarter ended June 30, 2026.
Disclosure under Regulation 30 (SEBI LODR) Outcome of Board Meeting
Investor Presentation
Unaudited Financials Results for Quarter ended June 30, 2026
Corrigendum to the Integrated Annual Report for the financial year 2025-26
Notice of 27th Annual General Meeting along with the Intergrated Annual report for FY 2025-26.
Earnings Conference Call
Rubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve The Un-Audited Standalone ....
Business Responsibility and Sustainabilty Report for the Financial Year 2025-26
Notice of 27th Annual General Meeting along with Integrated Annual Report of the Company for the financial year 2025-26 and Letter for weblink to access Notice and the Integrated Annual Report
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015 (''SEBI Listing Regulations'') - Acquisition of a Manufacturing Facility in USA.
Filing of Scheme of Merger of KIA Health Tech Private Limited (WOS) with Rubicon Research Limited - for disclosure purposes only, in terms of the Exemption under Para 4 of SEBI Master Circular ....
Filing of Scheme of Merger of KIA Health Tech Pvt Ltd (WOS) with Rubicon Research Limited - for Disclosure Purposes Only, in terms of the Exemption under Para 4 of SEBI Master circular ....
Date of 27th AGM and Record date for payment of final dividend.
Certificate under regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA inspection of Company''s manufacturing facility in Pithampur, Madhya Pradesh.
Intimation of Closure of Trading Window
Earning Call Transcript
Rubicon Newspaper Publication under reg 30
Earnings Call Audio Recording
Statement on Deviation/variation of Funds and further extension of timeline for utilization of IPO Proceeds.
Annual Secretarial Compliance Report for year ended March 31, 2026
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (SEBI Listing Regulations)
Board recommends dividend for year ended March 31, 2026
Outcome of the Board Meeting - Financial Results
The Board of Directors at its Meeting held on 29 May 2026, approved and recommended the formulation and adoption of New Employee Benefit Plan
Investor Presentation
Audited Financial Results for the quarter and year ended March 31, 2026, and recommendation of Dividend
Earnings Conference Call
Rubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting
Monitoring Agency Report for Quarter Ended March 31, 2026
Intimation under Reg 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) - Completion of Acquisition of securities in Arinna Lifesciences ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Outcome of USFDA inspection at the Company''s R&D facility in Canada.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Outcome of USFDA inspection at the Company''s R&D facility in Canada.
Intimation under regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)
Rubicon Research Limited Corporate Announcement for Acquisition
Press Release
Attached is the Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018.
Closure of Trading Window
Allotment of Equity shares pursuant to exercise of ESOPs
Outcome of Postal Ballot
Scrutinizer''s Report
Newspaper Publication - Notice of Postal Ballot
Earnings Call - Q3 FY 2025-26
Newspaper Publication - Financial Results
Outcome of the Board Meeting held on Tuesday, February 03, 2026
Annual Reports
12026
Concalls
2Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Held by ETFs
2 ETFs hold RUBICON · sorted by weight
Held by Mutual Funds
24 schemes hold RUBICON · sorted by weight